Evidence map›Paper›PMID 34497602›Full record

ArticleFrontiers in immunology2021

Long-Term Persistence and Relevant Therapeutic Impact of High-Titer Viral-Neutralizing Antibody in a Convalescent COVID-19 Plasma Super-Donor: A Case Report.

Mafalda De Rienzo, Maria Laura Foddai, Laura Conti, Chiara Mandoj, Stefano Iaboni, Ilenia Saladini, Concetta Castilletti, Giulia Matusali, Davide Roberto Donno, Luisa Marchioni and 6 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 90% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Mafalda De RienzoImmunohematology and Transfusional Medicine Unit, Regina Elena National Cancer Institute - IRCCS, Rome, Italy.
Maria Laura FoddaiImmunohematology and Transfusional Medicine Unit, Regina Elena National Cancer Institute - IRCCS, Rome, Italy.
Laura ContiClinical Pathology Unit and Cancer Biobank, Regina Elena National Cancer Institute - IRCCS, Rome, Italy.
Chiara MandojClinical Pathology Unit and Cancer Biobank, Regina Elena National Cancer Institute - IRCCS, Rome, Italy.
Stefano IaboniImmunohematology and Transfusional Medicine Unit, Regina Elena National Cancer Institute - IRCCS, Rome, Italy.
Ilenia SaladiniImmunohematology and Transfusional Medicine Unit, Regina Elena National Cancer Institute - IRCCS, Rome, Italy.
Concetta CastillettiVirology and Biosecurity Laboratories, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Rome, Italy.
Giulia MatusaliVirology and Biosecurity Laboratories, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Rome, Italy.
Davide Roberto DonnoDepartment of Infectious Diseases, National Institute for Infectious Diseases, "Lazzaro Spallanzani" - IRCCS, Rome, Italy.
Luisa MarchioniDepartment of Infectious Diseases, National Institute for Infectious Diseases, "Lazzaro Spallanzani" - IRCCS, Rome, Italy.
Stefania IannielloDepartment of Radiology, National Institute for Infectious Diseases, "Lazzaro Spallanzani" - IRCCS, Rome, Italy.
Angela CorpolongoDepartment of Infectious Diseases, National Institute for Infectious Diseases, "Lazzaro Spallanzani" - IRCCS, Rome, Italy.
Maria PalangeImmunohematology and Transfusional Medicine Unit, San Camillo Forlanini Hospital, Rome, Italy.
Gennaro CilibertoRegina Elena National Cancer Institute - IRCCS, Rome, Italy.
Giulia PiaggioDepartment of Research, Technological Innovation & Advanced Diagnostics, Regina Elena National Cancer Institute - IRCCS, Rome, Italy.
Federico De MarcoDepartment of Research, Technological Innovation & Advanced Diagnostics, Regina Elena National Cancer Institute - IRCCS, Rome, Italy.
Istituti di Ricovero e Cura a Carattere Scientifico · ITIstituto Nazionale per le Malattie Infettive Lazzaro Spallanzani · ITCarlo Forlanini Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A convalescent, non-severe, patient with COVID-19 was enrolled as a hyper-immune plasma voluntary donor by the Immuno-Hematology and Transfusion Unit of the Regina Elena National Cancer Institute in Rome, under the TSUNAMI national study criteria. During a nearly 6-month period (May-October 2020), the patient was closely monitored and underwent four hyperimmune plasma collections. Serum SARS-CoV-2 (anti-S + anti-N) IgG and IgM, anti-S1 IgA, and neutralizing titers (NTs) were measured. Anti-SARS-CoV-2 antibody levels steadily decreased. No correlation was found between anti-S/anti-N IgG and IgM levels and viral NT, measured by either a microneutralization test or the surrogate RBD/ACE2-binding inhibition test. Conversely, NTs directly correlated with anti-S1 IgA levels. Hyperimmune donor plasma, administered to five SARS-CoV-2 patients with persistent, severe COVID-19 symptoms, induced short-term clinical and pathological improvement. Reported data suggest that high NTs can persist longer than expected, thus widening hyperimmune plasma source, availability, and potential use.

Indexed as

AgedAntibodies, NeutralizingAntibodies, ViralBlood DonorsCOVID-19COVID-19 SerotherapyHumansImmunization, PassiveImmunoglobulin AMaleMiddle AgedSARS-CoV-2Spike Glycoprotein, CoronavirusTime FactorsTreatment OutcomeAntibodies, NeutralizingAntibodies, ViralImmunoglobulin ASpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2case reportCOVID-19hyperimmune plasmaIgAneutralizing antibodiesRBD/ACE2-binding inhibition test

Identifiers

PMID34497602
PMCPMC8419417
OpenAlexW3193736482

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.